Robert William O'Neill

US Patent:

6890710, May 10, 2005

Filed:

May 19, 1995

Appl. No.:

08/444994

Inventors:

Peter Palese - Leoma NJ, US
Robert O'Neill - New York NY, US

Assignee:

Mount Sinai School of Medicine of New York University - New York NY

International Classification:

C12Q001/70

US Classification:

435 5, 435 71, 4242061

Abstract:

The present invention relates to the identification of host cell proteins that interact with viral proteins required for virus replication, and high throughput assays to identify compounds that interfere with the specific interaction between the viral and host cell protein. Interfering compounds that inhibit viral replication can be used therapeutically to treat viral infection. The invention is based, in part, on the Applicants' discovery of novel interactions between proteins of the influenza virus and a human host cell proteins. One of these host cell proteins, referred to herein as NPI-1, interacts with influenza virus protein NP, and may be an accessory protein required for replication of influenza virus. Another of these host cell proteins, referred to herein as NS1I-1, interacts with influenza virus protein NS. Compounds that interfere with the binding of the host cell and viral proteins, and inhibit viral replication can be useful for treating viral infection in vivo.

US Patent:

7498424, Mar 3, 2009

Filed:

Nov 24, 2003

Appl. No.:

10/724273

Inventors:

Peter Palese - Leonia NJ, US
Robert O'Neill - New York NY, US

Assignee:

Mount Sinai School of Medicine of New York University - New York NY

International Classification:

C07H 21/02

US Classification:

536 231, 4242091

Abstract:

The present invention relates to the identification of host cell proteins that interact with viral proteins required for virus replication, and high throughput assays to identify compounds that interfere with the specific interaction between the viral and host cell protein. Interfering compounds that inhibit viral replication can be used therapeutically to treat viral infection. The invention is based, in part, on the Applicants' discovery of novel interactions between proteins of the influenza virus and a human host cell proteins. One of these host cell proteins, referred to herein as NPI-1, interacts with influenza virus protein NP, and may be an accessory protein required for replication of influenza virus. Another of these host cell proteins, referred to herein as NS1I-1, interacts with influenza virus protein NS. Compounds that interfere with the binding of the host cell and viral proteins, and inhibit viral replication can be useful for treating viral infection in vivo.

US Patent:

7632801, Dec 15, 2009

Filed:

Jan 6, 2003

Appl. No.:

10/337213

Inventors:

Peter M. Palese - Leonia NJ, US
Robert O'Neill - Yonkers NY, US
Ronald Harty - Bensalem PA, US

Assignee:

Mount Sinai School of Medicine of New York University - New York NY

International Classification:

A61K 38/00
A61K 38/08
A61K 38/10
C07K 4/00
C07K 4/02
C07K 7/00

US Classification:

514 2, 530300, 530326, 530327

Abstract:

The present invention relates to the identification of host cell proteins that interact with viral proteins required for virus replication, and high throughput assays to identify compounds that interfere with the specific interaction between the viral and host cell protein. Interfering compounds that inhibit viral replication can be used therapeutically to treat viral infection. The invention is based, in part, on the Applicants' discovery of novel interactions between viral proteins and a human host cell proteins. One of these host cell proteins, referred to herein as NPI-1, interacts with influenza virus protein NP. Also, host cell proteins, referred to herein as NS1I-1 and NS1-BP interact with influenza virus protein NS. In addition, host cell proteins containing WW domains that interact with viral proteins such as Rhabdoviral M protein are described. Compounds that interfere with the binding of the host cell and viral proteins, and inhibit viral replication can be useful for treating viral infection in vivo.

US Patent:

57503940, May 12, 1998

Filed:

May 20, 1994

Appl. No.:

8/246583

Inventors:

Peter Palese - Leonia NJ
Robert O'Neill - New York NY

Assignee:

The Mount Sinai Medical Center - New York NY

International Classification:

C12N 121
C12N 1563
C12N 510
C07H 2104

US Classification:

4352523

Abstract:

The present invention relates to the identification of host cell proteins that interact with viral proteins required for virus replication, and high throughput assays to identify compounds that interfere with the specific interaction between the viral and host cell protein. Interfering compounds that inhibit viral replication can be used therapeutically to treat viral infection. The invention is based, in part, on the discovery described herein of a novel interaction between the NP of influenza virus and a human host cell protein. The host cell protein, referred to herein as NPI-1, may be an accessory protein required for replication of influenza virus. Compounds that interfere with the binding of the host cell and viral proteins, and inhibit viral replication can be useful for treating viral infection in vivo.